vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and NewAmsterdam Pharma Co N.V. (NAMSW), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $32.0K, roughly 10592.7× NewAmsterdam Pharma Co N.V.). HAEMONETICS CORP runs the higher net margin — 13.2% vs -234134.4%, a 234147.6% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (-2.7% vs -99.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $-41.0M). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (0.4% CAGR vs -84.9%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
HAE vs NAMSW — Head-to-Head
Income Statement — Q3 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $32.0K |
| Net Profit | $44.7M | $-74.9M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | -206187.5% |
| Net Margin | 13.2% | -234134.4% |
| Revenue YoY | -2.7% | -99.7% |
| Net Profit YoY | 19.3% | 18.7% |
| EPS (diluted) | $0.95 | $-0.62 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $339.0M | $32.0K | ||
| Q3 25 | $327.3M | $348.0K | ||
| Q2 25 | $321.4M | $19.1M | ||
| Q1 25 | $330.6M | $3.0M | ||
| Q4 24 | $348.5M | $12.8M | ||
| Q3 24 | $345.5M | $29.1M | ||
| Q2 24 | $336.2M | $2.3M | ||
| Q1 24 | — | $1.4M |
| Q4 25 | $44.7M | $-74.9M | ||
| Q3 25 | $38.7M | $-72.0M | ||
| Q2 25 | $34.0M | $-17.4M | ||
| Q1 25 | $58.0M | $-39.5M | ||
| Q4 24 | $37.5M | $-92.2M | ||
| Q3 24 | $33.8M | $-16.6M | ||
| Q2 24 | $38.4M | $-39.0M | ||
| Q1 24 | — | $-93.8M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | -206187.5% | ||
| Q3 25 | 17.9% | -15845.7% | ||
| Q2 25 | 16.8% | -186.1% | ||
| Q1 25 | 21.6% | -2314.5% | ||
| Q4 24 | 16.9% | -338.5% | ||
| Q3 24 | 15.0% | -85.9% | ||
| Q2 24 | 11.8% | -2306.9% | ||
| Q1 24 | — | -3960.2% |
| Q4 25 | 13.2% | -234134.4% | ||
| Q3 25 | 11.8% | -20691.1% | ||
| Q2 25 | 10.6% | -90.7% | ||
| Q1 25 | 17.5% | -1327.3% | ||
| Q4 24 | 10.8% | -721.7% | ||
| Q3 24 | 9.8% | -57.2% | ||
| Q2 24 | 11.4% | -1711.6% | ||
| Q1 24 | — | -6692.9% |
| Q4 25 | $0.95 | $-0.62 | ||
| Q3 25 | $0.81 | $-0.61 | ||
| Q2 25 | $0.70 | $-0.15 | ||
| Q1 25 | $1.17 | $-0.34 | ||
| Q4 24 | $0.74 | $-0.91 | ||
| Q3 24 | $0.66 | $-0.18 | ||
| Q2 24 | $0.74 | $-0.41 | ||
| Q1 24 | — | $-1.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $636.2M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $683.4M |
| Total Assets | $2.5B | $769.3M |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $363.4M | $636.2M | ||
| Q3 25 | $296.4M | $702.9M | ||
| Q2 25 | $292.9M | $739.2M | ||
| Q1 25 | $306.8M | $808.5M | ||
| Q4 24 | $320.8M | $834.2M | ||
| Q3 24 | $299.3M | $422.7M | ||
| Q2 24 | $344.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $683.4M | ||
| Q3 25 | $849.2M | $728.1M | ||
| Q2 25 | $882.3M | $778.5M | ||
| Q1 25 | $820.8M | $777.4M | ||
| Q4 24 | $906.9M | $757.5M | ||
| Q3 24 | $878.9M | $378.9M | ||
| Q2 24 | $905.4M | $387.4M | ||
| Q1 24 | — | $411.8M |
| Q4 25 | $2.5B | $769.3M | ||
| Q3 25 | $2.4B | $786.4M | ||
| Q2 25 | $2.5B | $815.1M | ||
| Q1 25 | $2.5B | $818.4M | ||
| Q4 24 | $2.5B | $864.6M | ||
| Q3 24 | $2.5B | $439.2M | ||
| Q2 24 | $2.5B | $446.7M | ||
| Q1 24 | — | $488.5M |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $-40.9M |
| Free Cash FlowOCF − Capex | $87.2M | $-41.0M |
| FCF MarginFCF / Revenue | 25.7% | -128046.9% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 1.9% | 312.5% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | 2.09× | — |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $-148.0M |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $93.6M | $-40.9M | ||
| Q3 25 | $111.3M | $-32.8M | ||
| Q2 25 | $17.4M | $-37.7M | ||
| Q1 25 | $116.6M | $-36.5M | ||
| Q4 24 | $43.8M | $-37.5M | ||
| Q3 24 | $48.8M | $-12.5M | ||
| Q2 24 | $-27.4M | $-54.0M | ||
| Q1 24 | — | $-54.6M |
| Q4 25 | $87.2M | $-41.0M | ||
| Q3 25 | $106.3M | $-32.8M | ||
| Q2 25 | $13.6M | $-37.8M | ||
| Q1 25 | $100.9M | $-36.5M | ||
| Q4 24 | $35.2M | $-37.5M | ||
| Q3 24 | $39.4M | $-12.6M | ||
| Q2 24 | $-33.1M | $-54.2M | ||
| Q1 24 | — | $-55.0M |
| Q4 25 | 25.7% | -128046.9% | ||
| Q3 25 | 32.5% | -9428.4% | ||
| Q2 25 | 4.2% | -197.2% | ||
| Q1 25 | 30.5% | -1225.1% | ||
| Q4 24 | 10.1% | -293.5% | ||
| Q3 24 | 11.4% | -43.2% | ||
| Q2 24 | -9.8% | -2377.7% | ||
| Q1 24 | — | -3924.8% |
| Q4 25 | 1.9% | 312.5% | ||
| Q3 25 | 1.5% | 12.1% | ||
| Q2 25 | 1.2% | 0.5% | ||
| Q1 25 | 4.7% | 0.5% | ||
| Q4 24 | 2.5% | 0.0% | ||
| Q3 24 | 2.7% | 0.3% | ||
| Q2 24 | 1.7% | 9.2% | ||
| Q1 24 | — | 27.5% |
| Q4 25 | 2.09× | — | ||
| Q3 25 | 2.88× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 2.01× | — | ||
| Q4 24 | 1.17× | — | ||
| Q3 24 | 1.44× | — | ||
| Q2 24 | -0.71× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
NAMSW
Segment breakdown not available.
